Zydus Cadila to Test its COVID-19 Vaccine for 5-12 Years Age Group
Updated On Sep 08, 2021
Zydus Cadila group is planning to test its COVID-19 vaccine, ZyKov-D vaccine for children between 5 to 12 years of age. ZyKov-D is a plasmid DNA vaccine that belongs to the category of ‘nucleic acid’ vaccines. The Ahmedabad-based pharmaceutical company is looking forward to getting approval for emergency use of its COVID-19 vaccine in adults by June-end or July, 2021. It must be noted that Zydus Cadila had carried out over 800 clinical trials for its vaccine for adults and children aged between 12 and 18 years.
Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited reportedly stated that the company has a significant amount of data and if everything goes well, the vaccine will be granted approval for usage in children aged 12 to 18 years. He also added that ZyKov-D will be highly useful for children due to no side-effects and ‘needle free’ administration.
At present, Zydus Cadila is planning to perform human clinical trials for ZRC-3308. It must be noted that ZRC-3308 is a monoclonal antibody cocktail for mild COVID-19 treatment. The company seeks permission from the Drugs Controller General of India (DCGI) for the same. In animal toxicology studies, it has been found that ZRC-3308 is safe and well-tolerated.
Reports suggest that Zydus is the only Indian company to have developed a neutralizing monoclonal antibody-based cocktail for treating the novel coronavirus.
You may also like to read:
Disclaimer: This article is issued in the general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.